Preface by Feldmann, Marc et al.
Professor Ravinder Maini, known as ‘Tiny’ to all, has had a
most distinguished career as a rheumatologist, a clinical
immunologist, a clinical triallist, and the head of a large
academic research centre, the Kennedy Institute of
Rheumatology. He steered the institute into being one of
the world’s leading ‘translational’ research centres in
rheumatology and has received international recognition
for his many achievements: the American College of
Rheumatology awarded him the Distinguished Investigator
Award — he was the first non-US citizen to be thus
recognised — and the Université René Descartes of Paris
awarded him the degree of Doctor honoris causa. He has
been an enthusiastic teacher and mentor. Many of his
trainees, friends, and colleagues, past and present, are
participating in this conference and many have travelled
long distances to do so.
This volume and the corresponding website are designed
to fulfil two goals. First, they provide a summary of the pre-
sentations at the conference The Scientific Basis of
Rheumatology, held in London on 24–26 June 2002 at
the Royal College of Physicians. Secondly, they provide a
useful introduction and teaching aid for scientists entering
the field of rheumatology research. This multidisciplinary
area requires knowledge of a number of research fields,
including cytokines, cell signalling, matrix biology, vascular
biology, immunology, and inflammation. The website will
be continuously developed to enhance its teaching value.
We will seek volunteers to flesh it out with further interest-
ing and useful chapters.
When Tiny Maini started his scientific career at the
Kennedy Institute of Rheumatology (the flagship research
centre of the Arthritis Research Campaign, now at Imperial
College) in 1968, his early work examined the activities of
supernatants of lymphoid cell cultures. These bioactivities
were eventually purified to yield the cytokines. So it is
fitting that his best-known scientific contribution has been
in establishing that a single cytokine, tumour necrosis
factor alpha (TNF-α), is an important therapeutic target in
rheumatoid arthritis and that his best-known medical con-
tribution has been in leading the clinical trials that verified
that TNF-α blockade, using anti-TNF-α monoclonal anti-
body, was indeed effective. This work has been recog-
nized by the award of several prizes, most notably the
Crafoord Prize awarded by the Royal Swedish Academy in
2000, which was shared with Marc Feldmann and was a
fitting testimony to a successful collaboration spanning
almost 20 years. This work has led to the approval of two
drugs that are already widely used and two more in the
pipeline. At the time of writing, approximately 250,000
patients have been treated with anti-TNF therapy world-
wide, with significant benefits for patients who have
severe rheumatoid arthritis that does not respond to other
treatment.
The National Institute for Clinical Excellence (NICE) in the
UK is a government body set up to advise the National
Health Service on making new drugs available to patients.
It has evaluated anti-TNF therapy for rheumatoid arthritis
and appraised it as cost effective in March 2002. It should
now be more readily available for patients in the UK, and
this will be a source of much personal satisfaction to Tiny,
as the culmination of a glittering career.
The scientific meeting reported here was made possible
by significant contributions from Schering-Plough, Cento-
cor, and Roche Bioscience, and the publication and
website by a contribution from Abbott Laboratories. We
are very grateful for their support. The organizers of the
meeting, who are also the editors of these proceedings,
are long-term friends and admirers of Tiny Maini, and this
volume is dedicated to him with the warmest wishes for a
productive and enjoyable next stage of life.
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